![Moses Chen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Moses Chen
Directeur/Membre du Conseil chez
APOLLOMICS, INC.
Fortune : 51 223 $ au 31/05/2026
Profil
Hong-Jung Chen is currently Chairman & Chief Executive Officer at Maxpro Co., Ltd. since 2018.
Dr. Chen is also an Independent Director at Apollomics, Inc. and Apollomics, Inc. (United States) since 2023.
Former positions include Chairman & Chief Executive Officer at Maxpro Capital Acquisition Corp.
from 2021 to 2023, Managing Director at Maxpro Ventures Ltd. from 2018 to 2024, and Chief Operations Officer & Vice President at SyneuRx International (Taiwan) Corp.
from 2014 to 2017.
Education includes doctorate degrees from the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2026 | 3 620 ( 0,16% ) | 51 223 $ | 31/05/2026 |
Postes actifs de Moses Chen
| Sociétés | Poste | Début |
|---|---|---|
| APOLLOMICS, INC. | Directeur/Membre du Conseil | 30/03/2023 |
Maxpro Co., Ltd.
 Maxpro Co., Ltd. Financial ConglomeratesFinance Provides financial services and programming, scripts, indicators and automated-trading systems | Directeur Général | 01/05/2018 |
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Directeur/Membre du Conseil | 30/03/2023 |
Anciens postes connus de Moses Chen
| Sociétés | Poste | Fin |
|---|---|---|
Maxpro Ventures Ltd.
 Maxpro Ventures Ltd. Investment ManagersFinance Maxpro Ventures invests in companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceuticals, business development and finance sectors. It provides financing for early and later stage capital requirements. | Corporate Officer/Principal | 01/02/2024 |
| MAXO CAP | Directeur Général | 01/03/2023 |
| SYNEURX INTERNATIONAL (TAIWAN) CORP. | Directeur des opérations | 01/01/2017 |
Formation de Moses Chen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
6
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
University of Medicine & Dentistry of New Jersey
 University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SyneuRx International (Taiwan) Corp.
 SyneuRx International (Taiwan) Corp. BiotechnologyHealth Technology Researches and develops drugs to treat central nervous system disorders | Health Technology |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Health Technology |
Maxpro Co., Ltd.
Maxpro Co., Ltd. Financial ConglomeratesFinance Provides financial services and programming, scripts, indicators and automated-trading systems | Finance |
Maxpro Capital Acquisition Corp.
 Maxpro Capital Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Maxpro Ventures Ltd.
Maxpro Ventures Ltd. Investment ManagersFinance Maxpro Ventures invests in companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceuticals, business development and finance sectors. It provides financing for early and later stage capital requirements. | Finance |
Apollomics, Inc.
 Apollomics, Inc. Financial ConglomeratesFinance Operates as a biotechnology company that focuses on development of novel medicines for cancer patients | Finance |
Choisissez Zonebourse 
